LiquiTime™,
Oral Liquid Drug Delivery Platform For Pediatric And Geriatric Applications
LiquiTime (PDF file) allows the development of oral controlled release liquid formulations of drugs for patients who have difficulty swallowing tablets or capsules, such as children and the elderly.
LiquiTime has reached clinical proof of concept in humans for a liquid suspension of an undisclosed drug for treatment of children (confidential).
It is estimated that 50% of the population has problems swallowing tablets, especially children under 12 years of age and the elderly. With the increasing life expectancy in the developed as well as developing world and the decreasing birth rates in most of the developed countries, geriatric percentage of the population will dramatically increase in the coming decades from the current 10 % to 20 % of the population.
Key Benefits of LiquiTime
- Easy to swallow, good mouth feeling, taste masked
- Liquid formulations stable over 24 months
- Applicable to a wide range of drugs, not limited to ionic drugs as with resin-complex based technology
- Zero-order kinetics
- Combination of immediate release and extended release kinetics possible
- Combination in the same formulation of different drugs with different release kinetics possible
- Use “Generally Regarded as Safe” (GRAS) materials to warrant safety
- Rapid development time under cGMP conditions
- Ease to scale-up to industrial scale
- Clinical Proof of Concept achieved in humans; and,
- Broad and strong IP protection (several patents granted e.g. in the US, EU and Japan)
Publication
LiquiTime Oral Liquid Controlled Release Drug Delivery Platform
Rivail C. and Chatellier J. (2011) ONdrugDELIVERY “Oral drug delivery: Formulation selection methods & novel delivery technologies”
Issue May 2011: 20-21.